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Abstract
Objective—Different HIV-1 antigen specificities appear in sequence after HIV-1 transmission
and the immunoglobulin G (IgG) subclass responses to HIV antigens are distinct from each other.
The initial predominant IgG subclass response to HIV-1 infection consists of IgG1 and IgG3
antibodies with a noted decline in some IgG3 antibodies during acute HIV-1 infection. Thus, we
postulate that multiple antigen-specific IgG3 responses may serve as surrogates for the relative
time since HIV-1 acquisition.
Design—We determined the magnitude, peak, and half-life of HIV-1 antigen-specific IgG1 and
IgG3 antibodies in 41 HIV-1-infected individuals followed longitudinally from acute infection
during the first appearance of HIV-1-specific antibodies through approximately 6 months after
infection.
Methods—We used quantitative HIV-1-binding antibody multiplex assays and exponential
decay models to estimate concentrations of IgG1 and IgG3 antibodies to eight different HIV-1
proteins including gp140 Env, gp120 Env, gp41 Env, p66 reverse transcriptase, p31 Integrase, Tat,
Nef, and p55 Gag proteins during acute/recent HIV-1 infection.
Results—Among HIV-1-specific IgG3 responses, anti-gp41 IgG3 antibodies were the first to
appear. We found that anti-gp41 Env IgG3 and anti-p66 reverse transcriptase IgG3 antibodies, in
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addition to anti-Gag IgG3 antibodies, each consistently and measurably declined after acute
infection, in contrast to the persistent antigen-specific IgG1 responses.
Conclusion—The detailed measurements of the decline in multiple HIV-specific IgG3
responses simultaneous with persistent IgG1 responses during acute and recent HIV-1 infection
could serve as markers for detection of incident HIV infection.
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HIV-1 acute infection; HIV-1 incidence; immunoglobulin G subclass
Introduction
Recent studies of the earliest events following HIV-1 transmission by the transmitted/
founder virus demonstrate early destruction of B-cell generative microenvironments [1], and
that the initial antibody response ineffectively controls virus replication [2]. Detailed
understanding of the antibody specificities and subclasses elicited after HIV-1 transmission
can inform vaccine designs that aim to elicit functional antibodies more readily and more
robustly than natural HIV-1 infection. Furthermore, these specific antibody responses may
be used as a surrogate of the time since HIV-1 transmission. The latter idea is important
because antibody responses, potentially combined with other markers, can be used to define
incident HIV infection [3].
Current incidence tests are based on the evolution of the HIV-specific antibody response
during the first several months after transmission, wherein assays measuring the quantity or
avidity of HIV-specific antibodies can discriminate recent from chronic infection. One
commonly used strategy, the BED IgG-Capture Enzyme Immunoassay (BED EIA),
measures the proportion of HIV-1 gp41-specific binding antibodies to total immunoglobulin
G (IgG) from subtypes B, E, and D by a capture ELISA [4]. Other strategies, such as the
Abbott AxSYM HIV 1/2/gO, use a third-generation EIA that exploits the avidity maturation
of HIV-specific antibody response to determine time from transmission [5]. Although these
assays have been extensively used to determine incidence, they tend to result in a large
number of misclassified recent infections and may, therefore, overestimate incidence,
especially in non-clade B populations [6–8]. In addition, the ability of these assays to
accurately distinguish recent infection in individuals on antiretroviral therapy (ART) and
with low CD4 cell counts is difficult [9,10]. Additional measurements are needed that could
be used in a multivariate approach to increase specificity in the setting of non-clade B
infections and ART use.
Anti-Env HIV-1 plasma antibodies are predominantly IgG1 subclass, whereas anti-Env
IgG3 is the second most predominant IgG subclass [11]. Antibody effector functions (e.g.,
complement fixation, Fc receptor binding) are determined by antigen specificity and
antibody isotype and subclass, and anti-Env IgG1 and IgG3 are predominantly responsible
for antibody effector functions (reviewed in [12]). Differential regulation of anti-Env and
anti-Gag antibodies has been previously described [13] and anti-Gag IgG3 antibodies were
found more frequently in early infection [14–17]. Moreover, using western blot analyses,
Gag-specific IgG3 was shown to decline 1–4 months after infection [18], concordant with a
decrease in anti-HIV IgG3 during disease progression [15,17]. Although anti-Gag antibodies
do not have known direct antiviral activity, they may be indicative of an active T-helper-cell
response [13]. Furthermore, shorter duration of antigen-specific IgG subclasses may reflect
inherent differences in antibody subclass durability (i.e., IgG3) or that certain specificities
are from predominantly short-lived memory B cells.
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We determined the kinetics of HIV-specific IgG subclass antibody responses in an HIV-1
acute cohort from the USA, South Africa, and Malawi. Generally, there was an overall
decline in HIV-specific IgG3 responses in all individuals, whereas HIV-specific IgG1
responses tended to rise and remained elevated throughout the study period. We further
explored the applicability of HIV-specific IgG3 antibody responses to determining incidence
by applying an exponential decay model to determine the peak IgG3 antibody
concentrations as well as the half-life of these antibodies during acute HIV-1 infection
(AHI). In addition, we determined the effect of ART use, viral load, and individual location
on the peak and half-life of each HIV-specific IgG3 response. We propose that these
measurements could be part of a multivariate algorithm that could allow for an estimate of
the relative timing from HIV-1 transmission.
Methods
Participants
Plasma samples were collected over time from 41 participants enrolled during AHI, each
with between five and 15 visits. As shown in Table 1, 26 of the 41 participants (63.4%) were
from the USA and, of those, 11 (42.3%) began ART within 4 weeks of enrollment. An
additional two participants from the USA began ART at 12 and 16 weeks after enrollment.
No participants from South Africa/Malawi were on ARTwhile plasma samples were being
collected. Fifteen (36.5%) of the participants were whites and five (12.2%) were female.
Participants’ ages ranged from 17 to 60 years with an average age of 28.4 years. HIV-1
clade typing was done on a subset of participants at enrollment and virus clade corresponded
to location (clade B, North America; clade C, Africa) for each participant. CD4 cell counts
were done on most participants, but data was not obtained for all study visits (Supplemental
Digital Content 1, http://links.lww.com/QAD/A161). Viral load levels were also measured
for most visits for each participant (Supplemental Digital Content 2, http://links.lww.com/
QAD/A161) and viral load set point was determined by averaging all viral load
measurements within a defined set point window [19]. All participants were assigned to
Fiebig stages 1 through 6 upon enrollment into the Center for HIV-AIDS Vaccine
Immunology (CHAVI) 001 prospective study (Table 2) [20–22]. Upon enrollment, four
participants were in Fiebig stages I and II (viral RNA-positive only in stage I and viral
RNA-positive and p24 antigen-positive in stage II, antibody EIA nonreactive and occurring
approximately 10–24.3 days from transmission); four participants were in Fiebig stage III
(viral RNA, p24 antigen, EIA-positive, western blot-negative and occurring approximately
20.3–27.5 days from transmission); 11 participants were in Fiebig stage IV (viral RNA, p24
antigen, EIA-positive, western blot indeterminate and approximately 23.5–33.1 days from
transmission), and the rest of the participants (22) were in Fiebig stages V and VI (viral
RNA, p24 antigen, ELISA-positive, western blot-positive, p31 negative to positive in stage
VI, with stage Voccurring approximately 29.1–102.6 days from transmission).
This CHAVI Acute and Chronic Cohorts study was reviewed and approved by the
Institutional Review Boards of Duke University Medical Center. All participants provided
written informed consent for study participation.
HIV-1 multiplex-binding antibody assays
Customized multiplex HIV-1-binding assays were performed as previously described [2] to
determine IgG1 and IgG3 responses specific for recombinant HIV-1 p55 Gag (Protein
Sciences, Meriden, Connecticut, USA), recombinant HIV-1 gp41 MN (Immunodiagnostics,
Woburn, Massachusetts, USA), a previously described artificial multi-clade group M
consensus gp120 Env protein (Con6 gp120) (Drs Liao and Haynes, Duke University)[23],
HIV-1 p66 reverse transcriptase (RT) (Protein Sciences), HIV-1 recombinant Nef (Genway,
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San Diego, California, USA), recombinant HIV-1 Tat (Advanced Bioscience, Kensington,
Maryland, USA), and recombinant HIV-1 p31 Integrase (Genway) [2]. HIV-specific
antibody subclasses were detected with mouse antihuman IgG1 (BD Pharmingen, San
Diego, California, USA) and mouse antihuman IgG3 (Calbiochem, Gibbstown, New Jersey,
USA) on a Bio-Plex instrument (BioRad, Hercules, California, USA) and microgram per
milliliter equivalents were calculated using a 4PL curve analysis with IgG subclass
standards. Mouse antihuman IgG1 and IgG3 detection antibodies were tested for cross-
reactivity to IgG1, IgG2, IgG3, and IgG4 and found to be highly specific for subclass
detection. HIVIG (Quality Biological, Gaithersburg, Maryland, USA) and a constant HIV-
positive serum titration were utilized as positive controls and negative controls were
included in every assay. All assays were run under good clinical laboratory practice
compliant conditions, including tracking of positive controls by Levy–Jennings charts.
Positivity criteria (mean fluorescence intensity plus 3 standard deviations) for antibody–
antigen pairs were predetermined using a set of plasmas from 30-seronegative participants.
Food and Drug Administration compliant software, Bio-Plex Manager 5.0 (BioRad), was
utilized for the analysis of specimens.
Statistical analysis
To obtain estimates of peak antigen values and half-life, exponential decay models were
created for each antigen,
in which y is the antigen value, xt is the number of days after observed peak response for the
antigen of interest, β0 is the estimated peak value (level at day 0), and β1 is the exponential
rate of decay such that ln(2)/β1 is the estimated half-life. The models only include values at
or postpeak, assume an asymptote of zero, and a random effect for β0, and were fit using
PROC NLMIXED in SAS 9.2. Approximate 95% confidence intervals (CIs) for the half-life
estimates were generated based on a Student’s t-test distribution using the delta method to
estimate the variance of the half-life estimates. Specifically,
in which μ equals the estimate of β1 from the model. To explore the impact of ART, viral
load, and participant location status on antigen peak and half-life estimates, additional
models were created for each of these status variables that included subgroup-specific
estimates of peak value and half-life. Specifically,
in which subgroups are defined as use of ART (yes vs. no), viral load (≤5000 IU/ml vs.
>5000 IU/ml), and participant location (USA vs. South Africa/Malawi), and ART and viral
status are time-varying covariates such that values may change for a participant over time.
Because ART was only used in participants from the USA, the ART models included only
the USA participants. Likewise, the participant location models included only observations
prior to ART initiation. To compare the timing of peak between antigens, adjusted mean
estimates for each antigen at each visit were obtained from a longitudinal model that adjusts
for Fiebig staging at study enrollment in order to account for the differences in the amount
of time after infection upon enrollment.
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The models include all observed antigen values, treat each visit as a categorical variable, and
were fit using PROCMIXED in SAS 9.2.
Results
To evaluate the magnitude and kinetics of IgG subclass responses to AHI, we measured
HIV-specific IgG1 and IgG3 antibody responses in 41 individuals in the CHAVI 001 cohort.
Table 3 shows the seroprevalence of HIV-specific IgG1 and IgG3 antibodies in these
individuals. HIV-1 p55 Gag-specific and gp41Env-specific IgG1 was detected in all
participants, and IgG1 specific for p66 reverse transcriptase, p31 Integrase, and gp120 Env
was detected in at least 85% of participants. All 41 participants had detectable p55-specific
and gp41-specific IgG3, and IgG3 specific for p66 reverse transcriptase, p31 Integrase, and
gp120 Env was detected in most (>80%) but not all of the participants. HIV-1 Nef-specific
and Tat-specific IgG3 were detected in only 16 (39%) and 20 participants (49%),
respectively. These data show that IgG1 and IgG3 antibodies directed toward p55 Gag, gp41
Env, gp120 Env, and p66 reverse transcriptase are detectable in most participants during
AHI.
We previously showed that HIV gp41-specific antibodies are the first to arise during AHI
and they are followed by p55 Gag-specific, p66 reverse transcriptase-specific, gp120 Env-
specific, and p31 Integrase-specific antibodies [2,12]. To assess the postinfection timeframe
of the peak of the IgG3 and IgG1 antibody response, the visit at which the estimated mean
peak occurred was obtained from the longitudinal models that adjust for Fiebig staging (as
participants were enrolled at different Fiebig stages). The adjusted mean titers for HIV-1
gp41 Env-specific IgG3 peaked approximately 1 week after enrollment, followed by p55
Gag-specific and p66 reverse transcriptase-specific IgG3 at 3 weeks after enrollment, gp120
Env-specific IgG3 at 4 weeks after enrollment, and p31 Integrase-specific IgG3 at 16 weeks
after enrollment (Fig. 1) [22]. HIV-specific IgG1 antibodies did not show an overall
discernable peak (Fig. 2b). These results show that, in contrast to HIV-specific IgG1, HIV-
specific IgG3 antibodies decline over time and the timing of the peak of individual HIV-
specific IgG3 antibody responses is a reflection of their sequential elicitation during AHI.
Levels of HIV-specific IgG1 and IgG3 antibodies were also examined through 43 weeks
after enrollment and models were attempted to estimate the half-life [ln(2)/β2] of each
antibody response. Figure 2 shows the kinetics of HIV-specific IgG1 and IgG3 antibody
responses during AHI. HIV-specific IgG3 showed an overall decline, whereas HIV-specific
IgG1 antibody levels remained more stable and, thus, would not fit the exponential decay
model. Therefore, half-life of the HIV-specific IgG1 antibody responses for all responding
participants could not be estimated and as such; these responses are aligned by enrollment
instead of peak response, as shown for HIV-specific IgG3 (Fig. 2). In Supplemental Digital
Content 3, http://links.lww.com/QAD/A161, HIV-specific IgG3 antibody responses are
aligned to enrollment and, therefore, the rise and decline of these responses can be observed
for individual participants. Using the exponential decay model, half-life was estimated for
p55 Gag-specific, gp41 Env-specific, gp120 Env-specific, p31 Integrase-specific, and p66
reverse transcriptase-specific IgG3 antibody responses, with gp120 Env-specific IgG3
having the shortest half-life estimate of 17.4 (95% CI 16.6, 18.3) days and p55 Gag-specific
IgG3 having the longest half-life estimate of 59.9 (95% CI 51.1, 68.7) days (Fig. 2 and
Table 4). Because Nef and Tat IgG3 antibody responses were detected in less than half of all
participants and would, therefore, not be very useful to determine incidence, the results of
the exponential decay model are not shown. These results demonstrate that HIV-specific
IgG3 antibodies tend to decline during AHI in a defined manner, whereas HIV-specific
IgG1 antibodies tend to remain stable or elevate over time.
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The exponential decay model was also used to obtain estimates for specific antibody
concentrations (95% CI) at the observed peak for p55 Gag-specific IgG3 and gp41-specific
IgG3, which were 4.67 (95% CI 1.76, 7.57) and 1.49 μg/ml (95% CI 0.37, 2.62),
respectively (Table 5). The peak titers for the other IgG3 specificities were 0.1 μg/ml or
less. The estimated fold decrease (95% CI) from the observed peak response to day 150
postpeak was 5.7 (95% CI 4.22, 7.12) for p55 Gag-specific IgG3 and 36.11 (95% CI 11.87,
60.35) for gp41 Env-specific IgG3. Estimated antibody concentrations declined to 0.82 μg/
ml for p55 Gag-specific IgG3 and 0.04 μg/ml for gp41 Env-specific IgG3 by 150 days from
the peak response. Together with the half-life values obtained from the exponential decay
model, these data show a measurable decline in HIV-specific IgG3 antibodies during AHI.
Antibody responses were also modeled to account for the effects of ART use, viral load
(≤5000 vs. >5000 IU/ml), location (USA, predominantly clade B or South Africa/Malawi,
predominantly clade C) on the half-life (Table 4), and peak concentration (Supplemental
Digital Content 4, http://links.lww.com/QAD/A161) of HIV-specific IgG3 responses. To
separate any possible effects of ART from location on antibody half-life, only participants
from the USA were evaluated for the effects of ART on IgG3 responses (because all but one
of the participants on ART were in the USA). ART significantly lengthened the half-life
estimate of p55 Gag-specific IgG3 responses: participants off ART had p55 Gag-specific
IgG3 responses with a half-life estimate of 22.10 (95% CI 17.57, 26.65) days and those on
ART had a longer half-life estimate of 47.40 (95% CI 44.37, 50.04) days. Because of the
variation in the kinetics of gp41 Env-specific IgG3 responses, the effects of ART on the
half-life of this response could not be ascertained. In contrast to its effects on the half-life of
p55 Gag-specific IgG3, ART significantly shortened the half-life estimate of p66 reverse
transcriptase-specific IgG3 responses by over two-fold: participants on ART had a half-life
estimate of 20.54 (95% CI 18.04, 23.05) days and those off ART had a half-life estimate of
50.11 (95% CI 44.09, 56.12) days (Table 4). ART also significantly shortened the half-lives
of p31 Integrase-specific and gp120 Env-specific IgG3 by 1.6-fold and 1.5-fold,
respectively. ART use significantly increased the peak concentration of gp120 Env-specific
IgG3 responses, but did not affect the peak concentrations of any of the other IgG3
responses (Supplemental Digital Content 4, http://links.lww.com/QAD/A161). Also,
because HIV-specific IgG1 antibodies did not decline during AHI and the exponential decay
model could not be applied, the influence of ARTon the kinetics of these responses was not
determined. In summary, ART use tends to prolong the IgG3 antibody response to p55 Gag,
but shortens the IgG3 antibody response to p66 reverse transcriptase, p31 Integrase, and
gp120 Env.
The effects of viral load and location on IgG3 antibody half-life and peak concentration
were also evaluated (Table 4). All 41 participants were analyzed for the effects of viral load
on the IgG3 response. Participants with a viral load of more than 5000 IU/ml had a
significantly longer IgG3 antibody half-life for responses to p55 Gag, p66 reverse
transcriptase, and gp120 Env. Viral load levels did not have an effect on the half-life of p31
Integrase-specific IgG3 and a final model could not be obtained for the effects of viral load
on gp41 Env-specific IgG3 half-life. Viral load levels did not significantly affect the peak
concentration of any of the HIV-specific IgG3 antibody responses (Supplemental Digital
Content 4, http://links.lww.com/QAD/A161).
For the evaluation of the effects of participant location on IgG3 antibody half-life and peak
concentration, only observations prior to ART initiation were analyzed. This eliminates any
possible influence of ART use that may interfere with the effects of location on IgG3
kinetics. We observed that participants in South Africa/Malawi had significantly longer
antibody half-lives for p66 reverse transcriptase, p31 Integrase, and gp120 Env IgG3
compared with participants in the USA (Table 4). Participants in South Africa/Malawi also
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had a longer antibody half-life for p55 Gag-specific IgG3, but the difference between
antibody half-lives in participants in the USA vs. South Africa/Malawi was not significant.
However, participants in South Africa/Malawi had a shorter gp41 Env-specific antibody
half-life compared with participants in the USA. There were no location-specific effects on
the peak of IgG3 antibody responses (Supplemental Digital Content 4, http://links.lww.com/
QAD/A161). Together, these results show that participants with viral load levels above 5000
IU/ml had longer IgG3 antibody half-lives for p55 Gag-specific, p66 reverse transcriptase-
specific, and gp120 Env-specific responses. In addition, participants in Africa had p66
reverse transcriptase-specific, p31 Integrase-specific, and gp120 Env-specific IgG3
responses that were of significantly longer duration compared with participants in the USA.
Discussion
Here, we have examined the HIV-specific IgG1 and IgG3 responses to AHI in a defined
manner and propose that these measurements can be used in an algorithm to determine
incident HIV-1 infection. Our focus was maintained on IgG1 and IgG3 subclasses, as HIV-
specific IgG2 antibodies are not detected in most individuals and the elicitation of HIV-
specific IgG4 may be delayed in comparison (reviewed in [12]). Here, we have found that,
although IgG1 and IgG3 responses are elicited to gp41 Env, p55 Gag, p66 reverse
transcriptase, gp120 Env, and p31 Integrase in a majority of participants, IgG3 responses to
these antigens typically decline. In contrast, HIV-1 IgG1 antibody levels are typically
maintained over the same period. We estimated the half-life of the HIV-specific IgG3
antibody response as well as determined concentrations of these antibodies at their peak and
nadir (approximately 150 days postpeak).
ART use was found to have a significant impact on the half-life of p55 IgG3, wherein the
antibody response of participants on ART had a two-fold longer half-life compared with
untreated participants. Although there was not enough CD4 cell count data available to
make an association in this study, this finding is consistent with the idea that the Gag-
specific antibody response may be more dependent on CD4 T-cell help than responses to
other HIV-1 antigens [13]. In contrast to p55 Gag-specific IgG3, the half-life of p66 reverse
transcriptase-specific, p31 integrase-specific, and gp120 Env-specific IgG3 was decreased in
participants on ART, suggesting that virus replication may be a more important factor than
CD4+ T-cell responses in maintaining particular HIV-specific antibody responses. There
was not enough CD4 cell count data available during visits in which the peak and
subsequent initial decline of IgG3 antibodies was observed to significantly determine the
effect of CD4 cell counts on specific antibody responses. Participants in Malawi/South
Africa had longer IgG3 antibody half-lives than participants in the USA for p66 reverse
transcriptase-specific, p31 Integrase-specific, and gp120 Env-specific responses. A similar,
though nonsignificant, trend was also observed for p55 Gag-specific IgG3 half-life.
Participant location had the opposite effect on gp41 Env-specific IgG3 half-life. As only
samples prior to ART initiation were evaluated in this particular analysis, these data suggest
that there are location-specific effects on the duration of HIV-specific IgG3 responses.
Importantly, there did not appear to be any significant clade-specific differences in the
ability of the antigens we used to detect HIV-specific antibodies in our participants. All 15
participants in Malawi/South Africa (predominantly clade C) were positive for p66 reverse
transcriptase-specific, p31 Integrase-specific, and gp120 Env-specific IgG3 (data not
shown). This is not surprising, given that p66 reverse transcriptase and p31 Integrase are
relatively conserved proteins and the gp120 Env that we used was an artificial multi-clade
group M consensus gp120 Env protein (Con6 gp120) [23].
In a recent clonal analyses of the initial HIV-1 reactive antibodies, increased levels of IgA
and IgG3 antigen-specific antibodies were identified in AHI when compared with vaccine-
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induced influenza antibodies [24]. Thus, some of the initial anti-HIV-1 antibody response
may be due to stimulation of specific subsets of B cells that preferentially switch from IgM
to IgG3, for example, marginal zone B cells [25]. In addition, the sequential appearance of
gp41-specfic IgG3 followed by p55 Gag-specific and gp120 Env-specific IgG3 is consistent
with our previous findings involving overall HIV-specific IgG responses [2]. These results
are also consistent with the finding that the initial HIV-1 gp41 Env-specific response is due
to stimulation of a preexisting pool of cross-reactive memory B cells that had been
previously activated by non-HIV-1 antigens (Liao et al., in preparation).
Using the antibody concentrations of Gag, Env, and reverse transcriptase at peak, at half-life
point and at 150 days, the relative time since transmission could be estimated for an
unknown sample. Strategies have been developed for the purpose of incidence testing
[4,26,27]. However, improved tests for cross-sectional incidence testing are needed, as
current testing paradigms may not accurately account for variables such as ART, CD4 cell
count, and chronic patient populations [6,9,28–31]. Evaluation of the timing and
concentrations of p55 Gag, gp41 Env, and p66 reverse transcriptase IgG3 antibodies as
reported here are some of the immune measurements that could be evaluated for the purpose
of improving incidence testing in global populations.
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Refer to Web version on PubMed Central for supplementary material.
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HIV-specific IgG3 antibody responses peak sequentially during acute HIV-1 infection.
Mean concentrations of HIV-specific IgG3 are shown in a longitudinal model in which
responses were aligned to study enrollment and adjusted for time after HIV-1 acquisition
according to the classification by Fiebig et al. [22].
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Levels of HIV-1-specific IgG1 remain stable, whereas HIV-1-specific IgG3 declines over
time during acute HIV-1 infection. Declining HIV-1-specific IgG3 antibody responses were
aligned according to the peak of each response, modeled over time, and response half-life
was estimated using the exponential decay model. Half-life in days (95% confidence
interval) and N (number of participants with at least one positive time point after peak) are
depicted in each panel (a). HIV-1-specific IgG1 antibody levels did not decline and,
therefore, were not fit to the exponential decay model. For this reason, IgG1 antibody
responses were aligned to enrollment into the study (b).
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Table 1
Clinical data for CHAVI 001 participants (n=41).
Blacks/whites/unknown 25/15/1
Mean age (range) 28.4 (17–60)
Male/female 36/5
USA/Malawi/South Africa 26/11/4
On ART/off ARTa 13/28
ART, antiretroviral treatment.
a
Thirteen participants began ART at some point prior to the last sample collection, with 11 participants starting ART within 4 weeks of enrollment.
Some participants had interrupted ART during the study.
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Table 2
Fiebig staging data for CHAVI 001 participants.
Fiebig stage Approximate timeframeafter transmission (days)a
Number of
participants
I and II 10–24.3 4
III 20.3–27.5 4
IV 23.5–33.1 11
V and VI Stage V=29.1–102.6; stage VI=98.6 – open ended 22
a
Derived from [22], allowing 10–14 days for the eclipse phase.
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Table 3
Seroprevalence of HIV-specific IgG1 and IgG3 antibodies during acute HIV-1 infection.
Positive number (%)
IgG1 (n=41) IgG3 (n=41)
p55 Gag 41 (100) 41 (100.0)
gp41 Env 41 (100) 41 (100.0)
p66RT 40 (97.6) 39 (95.1)
p31 Integrase 37 (90.2) 33 (80.5)
gp120 Env 35 (85.4) 35 (85.4)
Tat 9 (22.0) 20 (48.8)
Nef 19a (50.0) 16 (39.0)
a
n=38.
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Table 4
.Effects of antiretroviral use, viral load, and virus clade on IgG3 antibody half-life.
Half-life (days)
Antibody Response Model Estimate type Estimate 95% CI P value
IgG3 p55 Exponential decay model Overall 59.91 51.05–68.74 0.0092
Viral load only model Low 49.09 36.19–61.99
High 77.24 60.85–93.63
ART use only modela No 22.10 17.57–26.65 <0.0001
Yes 47.40 44.37–50.44
Location only modelc USA 13.59 0.70–26.49 0.0921
Africab 71.71 56.42–87.01
IgG3 p66 Exponential decay model Overall 52.14 44.67–59.61 0.0119
Viral load only model Low 42.41 33.39–51.43
High 62.7 49.96–75.44
ART use only modela No 50.11 44.09–56.12 <0.0001
Yes 20.54 18.04–23.05
Location only modelc USA 51.07 40.20–61.93 0.0146
Africa 74.66 60.23–89.10
IgG3 p31 Exponential decay model Overall 26.86 23.18–30.55
Viral load only model Low 25.04 19.84–30.23 0.2394
High 29.47 23.67–35.27
ART use only modela No 33.12 23.33–42.92 0.0046
Yes 20.44 16.84–24.05
Location only modelc USA 33.08 22.9–43.26 0.0039
Africa 40.57 28.50–52.64
IgG3 gp41 Exponential decay model Overall 28.99 23.56–34.42
Location only modelc USA 70.16 42.16–98.15 0.0001
Africa 24.96 19.13–30.78
IgG3 gp120 Exponential decay model Overall 17.43 16.58–18.28 0.0143
Viral load only model Low 11.65 7.23–16.06
High 17.57 16.83–18.30
ART use only modela No 17.49 17.15–17.83 <0.0001
Yes 11.33 10.41–12.26
Location only modelc USA 17.50 17.05–17.94 <0.0001
Africa 529.95 183.6–876.3




Malawi/South Africa, predominantly clade C.
c
Samples prior to start of ART only.
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Table 5









Specificity Est. 95% CI Est. 95% CI Est. 95% CI Est. 95% CI
p55 Gag 4.67 1.76–7.57 2.33 0.88–3.78 0.82 0.28–1.37 5.67 4.22–7.12
gp41 Env 1.49 0.37–2.62 0.75 0.18–1.31 0.04 0.00–0.08 36.11 11.87–60.35
p66 RT 0.03 0.02–0.05 0.0161 0.01–0.02 0.0044 0.0022–0.0065 7.35 5. 25–9.44
gp120 Env 0.05 0.00–0.10 0.03 0.0022,0.05 0.0001 0.00–0.0003 389.80 276.24–503.36
p31 0.01 0.01–0.01 0.0048 0.0027–0.0069 0.0002 0.0001–0.0003 47.97 22.5–73.43
CI, confidence interval; Est, estimate.
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